Cost-effectiveness Evaluation Of Therapy With Naratriptan And Rizatriptan For Migraine In Spain

The purpose of this study is to investigate the cost-effectiveness of naratriptan and rizatriptan therapy for migra ine at tacks. Methods: cost-effectiveness analysis from the healthcare financer perspective in Spain, using a model based on a decision tree, which incorporates the direct healthcare costs and the probabilities associated with each of the possible outcomes. The average cost-ef fect iveness rat io and incremental cost-effectiveness ratio were obtained. Results: the average cost-effectiveness ratio of rizatriptan was 91.99 Euro per unit of effectiveness, in contrast to 139.27 for naratriptan. When comparing the cheapest therapy (naratriptan) with the most effective one (rizatriptan), the incremental cost-effectiveness ratio was 7.93 Euro per unit of effectiveness gained. Conclusion: Rizatriptan proved to be more efficient than naratriptan for the treatment of acute migraine in te rms o f cos t -e f f ec t i veness , f r om the healthcare-provider perspective in Spain.